Intravenous resluzimab (IL-5 antibody)

Are you trying to bankrupt the hospital? This is incorrect. Reslizumab, a monoclonal antibody targeting interleukin-5 (IL-5), is only indicated for severe eosinophilic asthma refractory to standard therapies. Amy has mild to moderate asthma, and her exacerbation is clearly triggered by an infection, not by eosinophilic inflammation. There is no evidence to support using reslizumab in this setting. Go back and try again.